

Bancila, Diaconu și Asociații SPRL assisted the founders of CytoGenomic Medical Laboratory in the sale of a majority stake to FutureLife



Bancila, Diaconu și Asociații SPRL assisted the founders of CytoGenomic Medical Laboratory in the sale of a majority stake in CytoGenomic Medical Laboratory SRL, Romanian leading genetic laboratory and one of the most innovative providers of medical services, to FutureLife, an European leader in reproductive medicine.

Dr. Danae Stambouli, founder of CytoGenomic Medical Laboratory, will remain a significant shareholder and CEO, leading the company's expansion strategy.

Danae Stambouli: "I am very pleased with the contribution of Bancila, Diaconu și Asociații team to the completion of the transaction. I particularly appreciated their promptness, client-oriented approach, and commercial knowledge, which doubled their legal contribution and provided us with comfort throughout the negotiations."

Alexandra Siminiceanu, *Managing Associate at Bancila, Diaconu și Asociații SPRL*: "We thank the founders of CytoGenomic Medical Laboratory for the trust placed in us throughout this transaction, as well as for the opportunity to support the company's development alongside a partner of the caliber of FutureLife."

The **Bancila, Diaconu și Asociații SPRL** team that assisted CytoGenomic Medical Laboratory in this transaction consisted of **Radu Diaconu** (*Managing Partner*), **Ștefan Mantea** (*Director*), **Alexandra Siminiceanu** (*Managing Associate*) and **Miruna Coderie** (*Senior Associate*).

Bancila, Diaconu și Asociații SPRL (formerly Radu și Asociații SPRL) is a Romanian full-service law firm, offering both legal advisory services and assistance before the courts of law, with a significant tax policy and controversy (TPC) practice.

Bancila, Diaconu și Asociații SPRL is a member firm of Ernst & Young Global Ltd and part of the expanding EY Law global network, which has more than 2,400 lawyers and offices in over 90 jurisdictions.

Chambers Global 2019 has recognized firm's Corporate/M&A practice while Chambers Europe 2019, 2020 and 2021 have placed Tax Policy and Controversy practice on Band 1. The Legal 500 Europe, Middle East and Africa 2019, 2020 and 2021 have also ranked Commercial, Corporate/M&A practice, while the 2020 and 2021 editions placed Tax Policy and Controversy practice on Tier 1.